Literature DB >> 21150914

Disruption of frontal θ coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptoms.

Paul D Morrison1, Judith Nottage, James M Stone, Sagnik Bhattacharyya, Nigel Tunstall, Rudolf Brenneisen, David Holt, Daniel Wilson, Alex Sumich, Philip McGuire, Robin M Murray, Shitij Kapur, Dominic H Ffytche.   

Abstract

The main ingredient in cannabis, Δ(9)-tetrahydrocannabinol (THC), can elicit acute psychotic reactions in healthy individuals and precipitate relapse in schizophrenic patients. However, the neural mechanism of this is unknown. We tested the hypothesis that THC psychopathology is related to changes in electroencephalography (EEG) power or inter-regional coherence. In a within-subjects design, participants (n=16) were given intravenous THC (1.25 mg) or placebo under double-blind conditions, during EEG recordings. Using fast-Fourier transform, EEG data were analyzed for power and coherence in the delta (1-3.5 Hz), theta (3.5-7 Hz), alpha (8-13 Hz), beta (14-25 Hz), low-gamma (30-40 Hz), and high-gamma (60-70 Hz) bands during engagement in the n-back test of working memory (WM). Compared with placebo, THC evoked positive and negative psychotic symptoms, as measured by the positive and negative syndrome scale (p<0.001) and slowed WM performance (p<0.05). Under THC, theta power was specifically reduced, (p<0.001) regardless of WM load; however, the reduction showed no relationship with psychotic symptoms or WM impairment. Coherence between bi-frontal electrodes in the theta band was also reduced by THC (p<0.05) and these reductions correlated with the change-in positive psychotic symptoms (rho=0.79, p<0.001). Bi-frontal specificity was suggested by the absence of a relationship between psychotic symptoms and fronto-parietal coherence. The results reveal that the pro-psychotic effects of THC might be related to impaired network dynamics with impaired communication between the right and left frontal lobes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21150914      PMCID: PMC3055738          DOI: 10.1038/npp.2010.222

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  48 in total

1.  Event-related theta oscillations during working memory tasks in patients with schizophrenia and healthy controls.

Authors:  C Schmiedt; A Brand; H Hildebrandt; C Basar-Eroglu
Journal:  Brain Res Cogn Brain Res       Date:  2005-11-10

2.  Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types.

Authors:  Agnes L Bodor; István Katona; Gábor Nyíri; Ken Mackie; Catherine Ledent; Norbert Hájos; Tamás F Freund
Journal:  J Neurosci       Date:  2005-07-20       Impact factor: 6.167

3.  Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain.

Authors:  M Glass; M Dragunow; R L Faull
Journal:  Neuroscience       Date:  1997-03       Impact factor: 3.590

4.  Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex.

Authors:  S M Eggan; D S Melchitzky; S R Sesack; K N Fish; D A Lewis
Journal:  Neuroscience       Date:  2010-06-11       Impact factor: 3.590

5.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

Review 6.  Role of endogenous cannabinoids in synaptic signaling.

Authors:  Tamas F Freund; Istvan Katona; Daniele Piomelli
Journal:  Physiol Rev       Date:  2003-07       Impact factor: 37.312

7.  Neural synchrony in cortical networks: history, concept and current status.

Authors:  Peter J Uhlhaas; Gordon Pipa; Bruss Lima; Lucia Melloni; Sergio Neuenschwander; Danko Nikolić; Wolf Singer
Journal:  Front Integr Neurosci       Date:  2009-07-30

8.  Psychiatric illness in general practice. A detailed study using a new method of case identification.

Authors:  D P Goldberg; B Blackwell
Journal:  Br Med J       Date:  1970-05-23

9.  Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia.

Authors:  Mihály Hajós; William E Hoffmann; Bernát Kocsis
Journal:  Biol Psychiatry       Date:  2008-02-07       Impact factor: 13.382

10.  Gamma rhythms and beta rhythms have different synchronization properties.

Authors:  N Kopell; G B Ermentrout; M A Whittington; R D Traub
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

View more
  36 in total

1.  The effect of chronic cannabinoids on broadband EEG neural oscillations in humans.

Authors:  Patrick D Skosnik; Deepak C D'Souza; Adam B Steinmetz; Chad R Edwards; Jennifer M Vollmer; William P Hetrick; Brian F O'Donnell
Journal:  Neuropsychopharmacology       Date:  2012-06-20       Impact factor: 7.853

Review 2.  The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Authors:  Britta Hahn
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

3.  THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia.

Authors:  David D Aguilar; Andrea Giuffrida; Daniel J Lodge
Journal:  J Psychopharmacol       Date:  2015-10-28       Impact factor: 4.153

4.  Effects of eye dominance (left vs. right) and cannabis use on intermanual coordination and negative symptoms in schizophrenia patients.

Authors:  Inge Gorynia; Markus Schwaiger; Andreas Heinz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-05-04       Impact factor: 5.270

5.  Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.

Authors:  Jules A A C Heuberger; Zheng Guan; Olubukayo-Opeyemi Oyetayo; Linda Klumpers; Paul D Morrison; Tim L Beumer; Joop M A van Gerven; Adam F Cohen; Jan Freijer
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

6.  Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.

Authors:  Roger Hudson; Justine Renard; Christopher Norris; Walter J Rushlow; Steven R Laviolette
Journal:  J Neurosci       Date:  2019-09-30       Impact factor: 6.167

7.  Marijuana Legalization Will Cause Many Problems for Missouri Law Enforcement and Schools.

Authors:  David G Evans
Journal:  Mo Med       Date:  2019 May-Jun

Review 8.  Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention.

Authors:  F Markus Leweke; Juliane K Mueller; Bettina Lange; Stefan Fritze; Cristina E Topor; Dagmar Koethe; Cathrin Rohleder
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

9.  The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: summaries of oral sessions.

Authors:  Brandon Abbs; Rashmin M Achalia; Adegoke O Adelufosi; Ahmet Yiğit Aktener; Natalie J Beveridge; Savita G Bhakta; Rachael K Blackman; Emre Bora; M S Byun; Maurice Cabanis; Ricardo Carrion; Christina A Castellani; Tze Jen Chow; M Dmitrzak-Weglarz; Charlotte Gayer-Anderson; Felipe V Gomes; Kristen Haut; Hiroaki Hori; Joshua T Kantrowitz; Taishiro Kishimoto; Frankie H F Lee; Ashleigh Lin; Lena Palaniyappan; Meina Quan; Maria D Rubio; Sonia Ruiz de Azúa; Saddichha Sahoo; Gregory P Strauss; Aleksandra Szczepankiewicz; Andrew D Thompson; Antonella Trotta; Laura M Tully; Hiroyuki Uchida; Eva Velthorst; Jared W Young; Anne O'Shea; Lynn E Delisi
Journal:  Schizophr Res       Date:  2012-08-19       Impact factor: 4.939

Review 10.  Cannabis and development of dual diagnoses: A literature review.

Authors:  Rebecca C Hanna; Jessica M Perez; Subroto Ghose
Journal:  Am J Drug Alcohol Abuse       Date:  2016-09-09       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.